Home › Gout › NCT07367971

Drug-Drug Interaction Study of ABP-671 in Gout Patients

Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

* Adults 18-75 years with clinical diagnosis of gout.
* Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
* Cohort N: Normal renal function.
* Cohort R: Moderate renal impairment.

Exclusion Criteria:

* Clinically significant hepatic impairment.
* History of Allopurinol hypersensitivity.
* Pregnancy or breastfeeding.

About the study

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

What is being tested

• ABP-671 plus allopurinol (drug)

Sponsor: Atom Therapeutics Co., Ltd · Participants: 20 · Started: Jan 23, 2026

Contact the study team

• MaoE Sun · Phone: 13914017855

Official record on ClinicalTrials.gov — NCT07367971

Locations in the U.S.

Conditions

• Gout

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.